Changes in US stocks | Moderna (MRNA.US), which plans to issue US$2 billion convertible senior notes, falls by more than 5%

The Zhitong Finance App learned that on Thursday, Moderna (MRNA.US) opened low and went low. As of press release, the decline was more than 5%, and the market value was about US$56.6 billion. According to the news, Moderna will issue $2 billion worth of convertible premium notes. Earlier, Moderna and MSD jointly announced that the individualized cancer vaccine IntiSmeran and Keytruda (pabolizumab), jointly developed by the two sides, simultaneously achieved the two core endpoints of relapse-free survival (RFS) and survival without distant metastasis (DMFS) in phase III trial Interpath-001 for completely resected stage IIb to stage IV melanoma. This past week, the stock recorded a gain of nearly 130%.